Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

J&J claims success in study testing earlier Tecvayli use in multiple myeloma

Summary by biopharmadive.com
The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to later-line settings for the persistent blood cancer.

1 Articles

biopharmadive.combiopharmadive.com
Center

J&J claims success in study testing earlier Tecvayli use in multiple myeloma

The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to later-line settings for the persistent blood cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Thursday, October 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Johnson & Johnson icon

Johnson & Johnson

News
For You
SearchBlindspotLocal